Modulation of Protein Stability in Cancer Therapy

di Sakamoto • 2009 • dettagli prodotto

spedizione gratuita
normalmente disponibile
per la spedizione in 20-25 giorni lavorativi

da €114,39 a € 97,23
accedi o registrati per vedere le promozioni a te riservate

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

Aggiungi al carrello
Aggiungi alla lista dei desideri

DESCRIZIONE

This book contains chapters written by experts in the field of the ubiquitin proteasome system and cancer. The authors have summarized current information on ubiquitin ligases and proteasomes as potential targets for cancer therapy. Topics covered in the book include an overview of ubiquitin ligases, deubiquitinating enzymes, and the proteasome. Specific diseases resulting from deregulated ubiquitin ligases, such as Von-Hippel-Lindau disease and Fanconi anemia are also discussed. Finally, novel approaches and drugs to target proteins involved in sumoylation, ubiquitination, and degradation are described.Table of contents Protacs chimeric molecules to target cancer causing proteins for ubiquitination and degradation.- Topors and sumoylation in cancer therapy.- Ubistatins.- Novel roteasome inhibitors.- MDM2 inhibitors.- HSP90 inhibitors in cancer therapy.- Novel proteasome inhibitors in multiple myeloma.- Novel HDAC6 inhibitor.- Histone deacetylase inhibitors in prostate cancer.- The role of ISG15 in carcinogenesis.